Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $725.31 million. The enterprise value is $666.42 million.
| Market Cap | 725.31M |
| Enterprise Value | 666.42M |
Important Dates
The last earnings date was Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 90.89 million shares outstanding. The number of shares has increased by 24.46% in one year.
| Current Share Class | 90.89M |
| Shares Outstanding | 90.89M |
| Shares Change (YoY) | +24.46% |
| Shares Change (QoQ) | +1.24% |
| Owned by Insiders (%) | 7.00% |
| Owned by Institutions (%) | 3.44% |
| Float | 20.51M |
Valuation Ratios
The trailing PE ratio is 203.88 and the forward PE ratio is 37.12.
| PE Ratio | 203.88 |
| Forward PE | 37.12 |
| PS Ratio | 6.50 |
| Forward PS | 4.33 |
| PB Ratio | 7.12 |
| P/TBV Ratio | 7.47 |
| P/FCF Ratio | 250.45 |
| P/OCF Ratio | 187.08 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 46.41, with an EV/FCF ratio of 230.12.
| EV / Earnings | 100.20 |
| EV / Sales | 6.21 |
| EV / EBITDA | 46.41 |
| EV / EBIT | 55.38 |
| EV / FCF | 230.12 |
Financial Position
The company has a current ratio of 6.19, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.19 |
| Quick Ratio | 5.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.40 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 10.02% and return on invested capital (ROIC) is 6.30%.
| Return on Equity (ROE) | 10.02% |
| Return on Assets (ROA) | 5.29% |
| Return on Invested Capital (ROIC) | 6.30% |
| Return on Capital Employed (ROCE) | 8.39% |
| Revenue Per Employee | $185,259 |
| Profits Per Employee | $11,487 |
| Employee Count | 579 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 0.64 |
Taxes
In the past 12 months, GYRE has paid $3.46 million in taxes.
| Income Tax | 3.46M |
| Effective Tax Rate | 22.65% |
Stock Price Statistics
The stock price has decreased by -19.56% in the last 52 weeks. The beta is 7.06, so GYRE's price volatility has been higher than the market average.
| Beta (5Y) | 7.06 |
| 52-Week Price Change | -19.56% |
| 50-Day Moving Average | 7.78 |
| 200-Day Moving Average | 8.39 |
| Relative Strength Index (RSI) | 54.92 |
| Average Volume (20 Days) | 56,292 |
Short Selling Information
The latest short interest is 1.48 million, so 1.62% of the outstanding shares have been sold short.
| Short Interest | 1.48M |
| Short Previous Month | 1.54M |
| Short % of Shares Out | 1.62% |
| Short % of Float | 7.20% |
| Short Ratio (days to cover) | 21.89 |
Income Statement
In the last 12 months, GYRE had revenue of $107.27 million and earned $6.65 million in profits. Earnings per share was $0.04.
| Revenue | 107.27M |
| Gross Profit | 102.42M |
| Operating Income | 12.03M |
| Pretax Income | 15.27M |
| Net Income | 6.65M |
| EBITDA | 14.36M |
| EBIT | 12.03M |
| Earnings Per Share (EPS) | $0.04 |
Balance Sheet
The company has $60.05 million in cash and $1.17 million in debt, giving a net cash position of $58.88 million or $0.65 per share.
| Cash & Cash Equivalents | 60.05M |
| Total Debt | 1.17M |
| Net Cash | 58.88M |
| Net Cash Per Share | $0.65 |
| Equity (Book Value) | 137.42M |
| Book Value Per Share | 1.12 |
| Working Capital | 82.66M |
Cash Flow
In the last 12 months, operating cash flow was $3.88 million and capital expenditures -$981,000, giving a free cash flow of $2.90 million.
| Operating Cash Flow | 3.88M |
| Capital Expenditures | -981,000 |
| Free Cash Flow | 2.90M |
| FCF Per Share | $0.03 |
Margins
Gross margin is 95.48%, with operating and profit margins of 11.22% and 6.20%.
| Gross Margin | 95.48% |
| Operating Margin | 11.22% |
| Pretax Margin | 14.24% |
| Profit Margin | 6.20% |
| EBITDA Margin | 13.39% |
| EBIT Margin | 11.22% |
| FCF Margin | 2.70% |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.46% |
| Shareholder Yield | -24.46% |
| Earnings Yield | 0.92% |
| FCF Yield | 0.40% |
Analyst Forecast
The average price target for GYRE is $17.00, which is 113.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 113.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 20.55% |
| EPS Growth Forecast (5Y) | 64.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GYRE has an Altman Z-Score of 25.51 and a Piotroski F-Score of 4.
| Altman Z-Score | 25.51 |
| Piotroski F-Score | 4 |